Oclacitinib
|
|
|
- CAS-Nr.
- 1208319-26-9
- Englisch Name:
- Oclacitinib
- Synonyma:
- JAKi;Apoquel;Oclactinib;PF 03394197;Oclacitinib;PF03394197, >98%;Oclacitinib?, >98%;Dimethyl biphenyl-4;Oclacitinib USP/EP/BP;Oclacitinib PF-03394197
- CBNumber:
- CB52667354
- Summenformel:
- C15H23N5O2S
- Molgewicht:
- 337.44
- MOL-Datei:
- 1208319-26-9.mol
|
Oclacitinib Eigenschaften
- Schmelzpunkt:
- 226-228°C
- Dichte
- 1.316±0.06 g/cm3(Predicted)
- Dampfdruck
- 0Pa at 20-25℃
- storage temp.
- Refrigerator, Under inert atmosphere
- Löslichkeit
- DMSO (Slightly), Methanol (Slightly, Sonicated)
- pka
- 11.59±0.40(Predicted)
- Aggregatzustand
- Solid
- Farbe
- Off-White to Pale Beige
- InChI
- InChI=1S/C15H23N5O2S/c1-16-23(21,22)9-11-3-5-12(6-4-11)20(2)15-13-7-8-17-14(13)18-10-19-15/h7-8,10-12,16H,3-6,9H2,1-2H3,(H,17,18,19)/t11-,12-
- InChIKey
- HJWLJNBZVZDLAQ-HAQNSBGRSA-N
- SMILES
- [C@@H]1(CS(NC)(=O)=O)CC[C@@H](N(C)C2N=CN=C3NC=CC3=2)CC1
- LogP
- 1.38 at 35℃ and pH7
Sicherheit
- Risiko- und Sicherheitserklärung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H302 |
Gesundheitsschädlich bei Verschlucken. |
Akute Toxizität oral |
Kategorie 4 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P270, P301+P312, P330, P501 |
| H317 |
Kann allergische Hautreaktionen verursachen. |
Sensibilisierung der Haut |
Kategorie 1A |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P261, P272, P280, P302+P352,P333+P313, P321, P363, P501 |
|
| Sicherheit |
| P280 |
Schutzhandschuhe/Schutzkleidung/Augenschutz tragen. |
|
Oclacitinib Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Oclacitinib is an oral JAK inhibitor that is a drug approved by the U.S. Food and Drug Administration (FDA) for use in canine atopic dermatitis (AD). The U.S. FDA and the European Medical Association have approved a number of JAK inhibitors, including baricitinib, ruxolitinib, federatinib, tofacitinib, upadacitinib, oclacitinib, but some of these drugs are still being studied. Oclacitinib mainly shows activity against JAK1-dependent cytokines and also inhibits the function of JAK2-dependent cytokines. oclacitinib modifies the production of cytokines such as IL-4 and IL-13, which are crucial for B-cell proliferation and maturation in the pathogenesis of pemphigus foliaceus. Oclacitinib could interdict the effects of IL-6, a cytokine involved in the Toll-like receptor 4-originated signaling pathway in the bladder epithelial cells, and IL-8, which could theoretically contribute to a decreased defense against the urinary pathogens[1-4].
Verwenden
Oclacitinib is a novel Janus kinase (JAK) inhibitor with activity against cytokines involved in allergy.
Oclacitinib Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Oclacitinib Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 161)Lieferanten
1208319-26-9()Verwandte Suche:
- PF-03394197 (oclacitinib)
- Oclacitinib PF-03394197
- JAKi
- trans-N-Methyl-4-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-cyclohexanemethanesulfonamide
- CyclohexaneMethanesulfonaMide, N-Methyl-4-(Methyl-7H-pyrrolo[2,3-d]pyriMidin-4-ylaMino)-, trans-
- N-methyl-1-((1r,4r)-4-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclohexyl)methanesulfonamide
- N-Methyl-1-(trans-4-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclohexyl)methanesulfonamide
- Oclacitinib
- PF 03394197
- Oclacitinib?, >98%
- PF03394197, >98%
- Oclactinib
- PF03394197; PF 03394197
- Oclacitinib USP/EP/BP
- Dimethyl biphenyl-4
- Apoquel
- 1208319-26-9
- Inhibitors
